Solicitudes de Patente publicadas en los últimos 90 días / Patent Applications last 90 days publications
Nº publicación: US2016144013A1 26/05/2016
UNIV YALE [US]
The invention provides compositions and methods for preventing, treating and diagnosing infection by Salmonella enterica serovar typhi (S. typhi) and/or S. paratyphi, i.e., typhoid fever.
Nº publicación: US2016146813A1 26/05/2016
UNIV JOHNS HOPKINS [US]
The presently disclosed fluidic sensor system and method comprise multifunctional nanoprobe-enabled capture for early detection of chemical and/or biological pathogens in a liquid sample. This sensor system and method can be used for food and environmental monitoring.
Nº publicación: WO2016081716A1 26/05/2016
UNIV KANSAS STATE [US]
Methods of preventing or decreasing PEDv and/or Salmonella bacteria in animal feed, feed ingredients, and pet food are provided. The methods utilize generally safe chemical mitigants, such as medium chain fatty acids, essential oils, and sodium bisulfate. The chemical mitigants are introduced to the feed or feed ingredients at inclusion rates selected so as to prevent or decrease PEDv and/or Salmonella bacteria in the animal feed, feed ingredients, or pet food. The methods are particularly suitable for use in post-processing treatment of animal feed, feed ingredients, or pet food that will be transported and stored for multiple days or weeks.
Nº publicación: RU2014138021A 20/05/2016
A vaccine composition for birds comprising as an active ingredient a structure containing 0-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing 0-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole -cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.
Nº publicación: WO2016077453A1 19/05/2016
OHIO STATE INNOVATION FOUNDATION [US]
As disclosed herein, fructose-asparagine (F-Asn) is a primary nutrient utilized during Salmonella-mediated gastroenteritis. Engineered bacteria are disclosed that can compete with Salmonella for F-Asn and other nutrients and withstand Salmonella-induced inflammation. These bacterium can be used as probiotics to treat and prevent Salmonella-mediated gastroenteritis.
Nº publicación: US2016136257A1 19/05/2016
HARVARD COLLEGE [US]
The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.
Nº publicación: US2016136285A1 19/05/2016
WROCLAWSKIE CT BADAN EIT & SP Z O O [PL]
The subject of the present invention is an isolated antigen being an immunogenic form of the common enterobacterial antigen (ECA) of Gram-negative bacteria of the family Enterobacteriaceae: ECA combined with lipopolysaccharide (ECALPS); a glycoconjugate of inactivated form of this antigen with a protein, as well as compositions and vaccines containing such an antigen/glycoconjugate designed for the prevention and treatment infections caused by Gram-negative bacteria.
Nº publicación: US2016136256A1 19/05/2016
US HEALTH [US]
Abstract of the Disclosure Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.
Nº publicación: DE102014223430A1 19/05/2016
FRAUNHOFER-GESELLSCHAFT ZUR F\u00D6RDERUNG DER ANGEWANDTEN FORSCHUNG E V [DE]
Die Erfindung betrifft ein kompetitives Immunassay-Testsystem sowie ein Verfahren zum einfachen und schnellen Nachweis von in einer Probe enthaltenen Pyrogenen mittels der Pyrogen-Bindedomäne von Mustererkennungsrezeptoren. Das Testsystem umfasst einen Assayträger, aufweisend mindestens eine immobilisierte Pyrogen-Bindedomäne eines Mustererkennungsrezeptors mit einem markierten, verdrängbaren Liganden, wobei die Verdrängung des Liganden durch ein in der Probe enthaltenes Pyrogen durch eine Farbreaktion der Markierung angezeigt wird. Bevorzugt weist der Assayträger weiterhin mindestens ein immobilisiertes Ligandenfängerprotein auf, welches den verdrängten Liganden bindet und dadurch eine Farbreaktion der Markierung auslöst.
Nº publicación: WO2016073977A1 12/05/2016
Disclosed are devices, systems, and methods for the rapid and accurate detection of analytes, including Salmonella.
Nº publicación: AU2014322988A1 12/05/2016
UNIV MUENSTER WILHELMS
The present invention relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunmodulatory domains thereof, for use in immunotherapy. The present invention further relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunmodulatory domains thereof, for delivering cargo molecules into eukaryotic cells.
Nº publicación: US2016113883A1 28/04/2016
ENGENELC MOLECULAR DELIVERY PTY LTD [AU]
Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
Nº publicación: US2016115527A1 28/04/2016
ROKA BIOSCIENCE INC [US]
The invention relates to a method for testing a sample for the presence of a pathogenic Escherichia coli, the method including detecting the presence of (i) ecf and (ii) wzx and/or stx in the sample, wherein detection of (i) ecf and (ii) wzx and/or stx in the sample is taken as an indication that the sample includes pathogenic E. coli.
Nº publicación: US2016114025A1 28/04/2016
UNIV ARKANSAS [US]
TEXAS A & M UNIV SYS [US]
Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of enhancing an immune response to a vaccine vector by expressing a polypeptide of CD 154 capable of binding CD40 are also disclosed. Methods of developing a bacterial vaccine vector are disclosed. Methods of generating scarless site-specific mutations in a bacterium are also disclosed.
Nº publicación: KR20160045829A 27/04/2016
Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S.typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.
Nº publicación: CN105524862A 27/04/2016
Nº publicación: CN105531382A 27/04/2016
Methods of detecting target bacteria are provided. In some embodiments the methods comprise exposing the sample to a phage capable of infecting a set of target bacteria and comprising a heterologous nucleic acid sequence encoding a marker. In some embodiments the target bacteria comprise Listeria. In some embodiments the target bacteria are all Listeria. Recombinant Listeria phage comprising a heterologous nucleic acid sequence encoding a marker are also provided as are useful combinations of such phage and articles of manufacture comprising such phage, among other things.
Nº publicación: KR20160044637A 26/04/2016
Nº publicación: JP2016511633A 21/04/2016
The subject relates to an isolated antibody that specifically binds to O25b antigen of multi drug resistant (MDR) E. coli strains, its medical and diagnostic use, method of producing the antibody, including an isolated nucleotide sequence, plasmids and host cells as used in the production of the antibody; and further an isolated epitope recognized the specific antibody.
Nº publicación: US2016106106A1 21/04/2016
HONBU SANKEI CO LTD [JP]
The present invention provides microbe disinfectants, providing: Drug-resistant microbe disinfectants comprising a chlorous acid aqueous solution for inactivating microbes selected from methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus; and microbe disinfectants, which are made with acidity when applied to gram-negative microbes and with alkalinity when applied to gram-positive microbes. The microbes comprise at least one species of microbes selected from the group consisting of E. coli, Staphylococcus aureus, microbes of genus Bacillus, microbes of genus Paenibacillus, Pseudomonas aeruginosa, Enterococcus, Salmonella enterica, and periodontal disease microbes. The present invention is usable as a microbe disinfectant that is safe to human body and easy to handle as a microbe disinfectant for pretreatment in food processing and produces chlorous acid that generates little chlorine dioxide. The microbe disinfectant comprising a chlorous acid aqueous solution of the present invention can be utilized as a sterilizing agent, food additive, antiseptic, quasi-drug, medicine, etc.
Nº publicación: JP2016510973A 14/04/2016
The present invention relates to a method for screening a compound that inhibits secretion of toxins into host-cell cytoplasm by virulent bacteria using a needle type III secretion system. The compound of the invention is selected by screening for a compound which interacts with a loop region of the cytoplasmic domain of the membrane protein FlhB from Salmonella typhimurium or a paralog thereof. Compositions including the compound of the invention, use of the compound, and methods of treating disorders caused by virulent bacteria are also provided.
Nº publicación: CN105483051A 13/04/2016
Nº publicación: CN105483052A 13/04/2016
Nº publicación: CN105483049A 13/04/2016